Form 4: Alkermes Director Richard Gaynor Reports Stock Option Grant and RSU Acquisition

Director Richard Gaynor reports the acquisition of stock options and restricted stock units (RSUs) in Alkermes plc.

Summary

• Richard Gaynor, a director of Alkermes plc, filed a Form 4 disclosing transactions related to derivative securities.
• On May 31, 2024, Gaynor acquired 17,492 non-qualified stock options with an exercise price of $23.4, vesting fully on May 31, 2025, and expiring on May 31, 2034.
• Gaynor also acquired 8,013 restricted stock units (RSUs) on May 31, 2024, which vest fully on May 31, 2025.
• The filing also details adjustments to previously granted equity awards due to the separation of Alkermes' oncology business into Mural Oncology plc on November 17, 2023.
• The adjustments were made to preserve the value of the original awards based on the equity adjustment terms in the Employee Matters Agreement.
• Gaynor also holds various other non-qualified stock options that were granted prior to the separation and adjusted on November 17, 2023, with exercise prices ranging from $16.52 to $30.86 and expiration dates ranging from 2029 to 2033.
• A Power of Attorney document is included, granting authority to Samuel Parisi, Shantale Greenson, Stephanie Roche, Rob Puopolo, and Jeffrey Geary to act on Gaynor's behalf in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document primarily reports routine equity transactions. While the acquisition of stock options and RSUs can be seen as a positive sign of director confidence, it's a standard practice and doesn't necessarily indicate a significant shift in the company's outlook.

Positives

• The acquisition of stock options and RSUs by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the stock options and RSUs indicate a continued relationship between the director and the company.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation practices vary across the pharmaceutical industry, but stock options and RSUs are frequently used to incentivize executives and align their interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans for their directors and officers.
• The specific terms of these grants, such as vesting schedules and exercise prices, are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• The equity grants could potentially impact shareholders by diluting ownership, but they also align the director's interests with shareholder value creation.

Key Dates